3:35
The role of MRD in ALL: what defines a complete response?
Bijal Shah
1:25
The diagnosis of early T-cell precursor (ETP) ALL
Bijal Shah
2:56
Molecular subtypes of ALL: coming to a consensus
Bijal Shah
2:37
Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Naval Daver
2:05
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Naval Daver
3:31
Update on checkpoint inhibitor therapy for AML: salvage, frontline & azacitidine combination
Naval Daver
3:14
Targeting sonic hedgehog signaling in AML
Jorge Cortes
6:03
Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones
Ari Melnick et al.
8:13
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick et al.
11:57
The evolving genomic landscape of ALL: molecular genetics, profiling and classification
Anjali Advani et al.
10:31
Recent subtypes of ALL: Ph-like ALL and ETP ALL
Anjali Advani et al.
1:30
Determining the progression of SMM using predictive biomarkers
Irene Ghobrial
3:33
Next steps in gaining CLARITY on CLL
0:57
What can we learn about CLL by studying environmental stimuli?
Francesco Forconi
1:33
Understanding the mechanisms of venetoclax and ibrutinib resistance
Constantine Tam
1:11
Results and rational behind breakthrough therapy-designated E-selectin antagonist for AML
Daniel DeAngelo
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals